Lead Product(s) : RXRG001
Therapeutic Area : Dental and Oral Health
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RiboX IND Clearance for RXRG001, First Circular RNA Therapy
Details : RXRG001 is the first-ever circular RNA therapy candidate, which is currently being evaluated for the treatment of radiation-induced xerostomia and hyposalivation.
Product Name : RXRG001
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
October 25, 2024
Lead Product(s) : RXRG001
Therapeutic Area : Dental and Oral Health
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable